Stockscreener 앱 받기
2.77
1.42%
-0.04
시장 영업 전:
2.66
-0.11
-3.97%
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Price to book forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBIT forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Price to earnings forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBITDA forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Cellectar Biosciences, Inc. Actuals & Estimates (NASDAQ:CLRB) - TradingView
Enterprise value to revenue forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
CLRB Forecast — Price Target — Prediction for 2027 - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cellectar Biosciences Inc (CLRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cellectar Biosciences Inc (CLRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cellectar Biosciences Inc (CLRB) Institutional Confidence - TradingKey
Cellectar Biosciences (CLRB) Edges Higher: Consolidation Near Key ResistanceFund Manager Survey - newsline.com
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cellectar Biosciences Inc (CLRB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cellectar Biosciences (CLRB) Slides 4.27% as Support Test LoomsInstitutional Flow Picks - dars.gov.et
Number of shareholders of Cellectar Biosciences, Inc. – MUN:NV40 - TradingView
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38Swing Entry Signals - newsline.com
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesProfit Announcement - newsline.com
[EFFECT] Cellectar Biosciences, Inc. SEC Filing - Stock Titan
Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named - Stock Titan
Cellectar plans phase 3 trial for WM treatment after BTKi - Investing.com UK
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting - Investing News Network
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com - Investing.com South Africa
Cellectar Biosciences Q1 2026 earnings preview - MSN
Cellectar (NASDAQ: CLRB) details 51.9M-share resale tied to May 2026 financing - Stock Titan
Cellectar Biosciences (CLRB) upgraded to buy: Here's what you should know - MSN
Large warrant exercise and equity plan votes ahead for Cellectar (NASDAQ: CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Edges Higher: Support Levels Tested as Biotech Sector Shows Mixed SignalsFundamental Weighted - newsline.com
CLRBCellectar Biosciences Inc Stock Price and Quote - Finviz
Cellectar Biosciences Edges Higher, Finding Support Near $3.04Growth Stock Picks - The Legal Advocate
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar Biosciences Announces Board Changes and New Director - The Globe and Mail
Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan
Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView
Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan
Cellectar Biosciences, Inc. Announces Board Changes - marketscreener.com
User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN
CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart
0.05%
0.74%
자본화:
|
볼륨(24시간):